A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the pharmacodynamic (what the drug does to the body)
changes when transitioning from rivaroxaban 20 mg once daily to warfarin dosed to a
therapeutic level as measured by the International Normalized Ratio (INR) range of 2.0 to 3.0
in healthy volunteers. In addition, the pharmacokinetics (what the body does to the drug),
safety and tolerability of rivaroxaban during the transition to warfarin will be
investigated. The INR is obtained from a blood test, and is a measure for the clotting
tendency of the blood used for safe and adequate dosing of warfarin.